topotecan liposome

Topotecan liposome is a formulation of the chemotherapeutic agent topotecan encapsulated within a liposomal carrier. This delivery system is designed to enhance the pharmacokinetic profile and tumor targeting of topotecan by increasing its plasma half-life and reducing systemic toxicity compared to free drug administration[1][5]. Topotecan acts as an inhibitor of DNA topoisomerase I, stabilizing the enzyme-DNA complex and preventing religation of single-strand breaks during DNA replication. This leads to replication arrest and cell death in rapidly dividing cancer cells[6]. Liposomal encapsulation improves drug retention and allows for more efficient delivery into tumor cells via endocytosis or receptor-mediated uptake[2][3]. The formulation has been investigated for use in various cancers including neuroblastoma, ovarian cancer, small-cell lung cancer, cervical cancer, and lung tumors[1][2][5].

Brand names

BrakivaOptisomal topotecan

Other names

liposomal topotecanSphingosome-encapsulated topotecanliposomal topotecan hydrochloride